Targets › HEV
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease.
Open in Phaseline: the race on HEV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| International Vaccine Institute | Hecolin® Recombinant Hepatitis E Vaccine Recombinant hepatitis E virus (HEV) vaccine | HEV | Phase 2 | Hepatitis E Virus Infection | – |
Hepatitis E Virus Infection (1)
mixed (1)
International Vaccine Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.